Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Rises By 33.5%

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 49,000 shares, an increase of 33.5% from the March 15th total of 36,700 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 340,200 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Roth Mkm reissued a “buy” rating on shares of Tenax Therapeutics in a report on Tuesday, February 20th. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Wednesday, January 10th. They issued a “sell” rating for the company.

Institutional Investors Weigh In On Tenax Therapeutics

A hedge fund recently bought a new stake in Tenax Therapeutics stock. Vanguard Group Inc. purchased a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 186,046 shares of the specialty pharmaceutical company’s stock, valued at approximately $51,000. Vanguard Group Inc. owned approximately 62.02% of Tenax Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Stock Down 2.8 %

Shares of TENX stock opened at $3.76 on Monday. Tenax Therapeutics has a 1 year low of $3.48 and a 1 year high of $61.20. The stock has a fifty day moving average price of $4.55 and a 200 day moving average price of $15.22.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.